Ultram and Appetite disorder - a phase IV clinical study of FDA data

Summary:

Appetite disorder is reported as a side effect among people who take Ultram (tramadol hydrochloride), especially for people who are female, 60+ old, also take Lasix, and have Dizziness.

The phase IV clinical study analyzes which people have Appetite disorder when taking Ultram. It is created by eHealthMe based on reports of 26,802 people who have side effects when taking Ultram from the FDA, and is updated regularly.

What is Ultram?

Ultram has active ingredients of tramadol hydrochloride. It is often used in pain. eHealthMe is studying from 28,425 Ultram users. Check the latest studies of Ultram.

What is Appetite disorder?

Appetite disorder (abnormal eating habits) is found to be associated with 716 drugs and 706 conditions by eHealthMe. Check the latest studies of Appetite disorder.

On Jul, 05, 2026

26,802 people reported to have side effects when taking Ultram.
Among them, 66 people (0.25%) have Appetite disorder.

Among these 66 people:

What is the gender of people who have Appetite disorder when taking Ultram? *

female: 93.22 %
male: 6.78 %

What is the age of people who have Appetite disorder when taking Ultram? *

What are other drugs people take besides Ultram? *

What are other side effects people have besides Appetite disorder? *

Fatigue (feeling of tiredness): 58 people, 87.88%
Diarrhea: 55 people, 83.33%
Joint Pain: 55 people, 83.33%
Nausea And Vomiting: 54 people, 81.82%
Nausea (feeling of having an urge to vomit): 54 people, 81.82%
Gait Disturbance: 51 people, 77.27%
Chills (felling of cold): 51 people, 77.27%
Weakness: 51 people, 77.27%
Muscle Aches (muscle pain): 50 people, 75.76%
Hypoaesthesia (reduced sense of touch or sensation): 50 people, 75.76%

What are the existing conditions these people have? *

Dizziness: 37 people, 56.06%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 10 people, 15.15%
Breast Cancer: 10 people, 15.15%
Neuropathy Peripheral (surface nerve damage): 7 people, 10.61%
Primary Myelofibrosis (primary disorder of the bone marrow): 5 people, 7.58%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 4.55%
Joint Pain: 3 people, 4.55%
Depression: 2 people, 3.03%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 1.52%
B-Cell Small Lymphocytic Lymphoma (blood cancer affecting b cells): 1 person, 1.52%

* Approximation only. Some reports may have incomplete information.

Do you take Ultram and have Appetite disorder?

- Check whether Appetite disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ultram:

Ultram (28,425 reports)

Browse all side effects of Ultram:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Appetite disorder:

Appetite disorder (716 drugs)

Browse all the conditions that are associated with Appetite disorder:

Appetite disorder (706 conditions)

Related publications that referenced our studies

Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .
Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on tramadol hydrochloride (the active ingredients of Ultram) and Ultram (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.